Theravance Biopharma, Inc. (TBPH): M&A transaction — Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M

Theravance Biopharma, Inc.

Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.
Retains right to up to $150M in milestones from Royalty Pharma on 2025/2026 net sales.
First outcome from Strategic Review Committee formed Nov 2024; board committed to returning excess capital.
Total potential lifetime value from Trelegy monetization now $1.525B including prior $1.1B upfront.
2025 financial guidance unchanged; company continues to focus on YUPELRI and ampreloxetine.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Theravance Biopharma, Inc. completed a disposition involving GlaxoSmithKline Intellectual Property Development Limited for $225 million (closed 2025-05-30).

Action: disposition
Counterparty: GlaxoSmithKline Intellectual Property Development Limited
Consideration: $225 million
Closing: 2025-05-30

Exact text from the filing

ompany (“TBPH”) and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered

View on SEC.gov

Browse all m&a transactions →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-055100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.